A Case Series of Cabazitaxel Re-Challenge Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer who Have Previously Received Docetaxel and Cabazitaxel Chemotherapy

Madam — Due to the upfront use of docetaxel chemotherapy in patients with metastatic prostate cancer, there is a therapeutic conundrum for subsequent treatment at the time of progressive disease. Cabazitaxel has been established as a second-line chemotherapy option by the TROPIC trial [1], but concerns regarding toxicity mean it has not been adopted into widespread use. However, improved quality of life and modest toxicity have been reported by a recent UK early access programme [2]. There will probably be a renewed interest in both docetaxel and cabazitaxel chemotherapy in patients with metastati c castrate-resistant prostate cancer (mCRPC) who have had previously good symptomatic ± biochemical responses.
Source: Clinical Oncology - Category: Radiology Authors: Tags: Letter Source Type: research